{"id":"pegylated-ifn-alfa-2b-plus-ribavirin","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-15","effect":"Hemolytic anemia"},{"rate":"5-10","effect":"Neutropenia"},{"rate":"5-10","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression/mood changes"},{"rate":"20-30","effect":"Headache"},{"rate":"20-30","effect":"Nausea"},{"rate":"5-10","effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegylated IFN alfa-2b is a long-acting formulation of interferon alfa-2b that binds to interferon-alpha receptors on immune cells, inducing antiviral and antiproliferative effects. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and reduces viral replication. The combination has synergistic activity against hepatitis C virus by enhancing immune clearance and directly suppressing viral replication.","oneSentence":"Pegylated interferon alfa-2b activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:12.552Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"}]},"trialDetails":[{"nctId":"NCT01340573","phase":"","title":"Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-23","conditions":"Chronic Hepatitis C","enrollment":3},{"nctId":"NCT01440595","phase":"PHASE2","title":"Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-28","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT00015652","phase":"NA","title":"Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":24},{"nctId":"NCT01425203","phase":"PHASE3","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-23","conditions":"Chronic Hepatitis C Genotype 1","enrollment":238},{"nctId":"NCT01710501","phase":"PHASE2","title":"A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Chronic Hepatitis C (CHC)","enrollment":87},{"nctId":"NCT00237484","phase":"PHASE3","title":"Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07-18","conditions":"Hepatitis C, Chronic","enrollment":89},{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT01606800","phase":"PHASE4","title":"Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-01","conditions":"Hepatitis C, Chronic","enrollment":45},{"nctId":"NCT01370642","phase":"PHASE3","title":"Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":294},{"nctId":"NCT02358044","phase":"PHASE3","title":"Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-27","conditions":"Hepatitis C","enrollment":257},{"nctId":"NCT01390844","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-21","conditions":"Hepatitis C, Chronic","enrollment":282},{"nctId":"NCT00803309","phase":"PHASE4","title":"Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients","status":"TERMINATED","sponsor":"HepNet Study House, German Liverfoundation","startDate":"2008-11","conditions":"Hepatitis C, Chronic","enrollment":99},{"nctId":"NCT02099604","phase":"PHASE3","title":"Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C","status":"WITHDRAWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-04","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT00493805","phase":"PHASE4","title":"Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Hepatitis C, Chronic, Insulin Resistance","enrollment":59},{"nctId":"NCT00423800","phase":"PHASE3","title":"Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12","conditions":"Hepatitis C, Chronic","enrollment":56},{"nctId":"NCT00959699","phase":"PHASE2","title":"A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"HIV Infections, Hepatitis C, HCV Infection","enrollment":99},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00686777","phase":"PHASE4","title":"Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":75},{"nctId":"NCT00863109","phase":"","title":"Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04","conditions":"Hepatitis C, Chronic, Genotype 1, HCV-1","enrollment":133},{"nctId":"NCT00759109","phase":"PHASE3","title":"Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-03","conditions":"Carcinoma, Hepatocellular","enrollment":150},{"nctId":"NCT00255034","phase":"PHASE4","title":"Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":146},{"nctId":"NCT00378599","phase":"PHASE3","title":"Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Liver Transplantation, Hepatitis C, Chronic, Liver Cirrhosis","enrollment":125},{"nctId":"NCT00255008","phase":"PHASE4","title":"Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT00265395","phase":"PHASE3","title":"Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-12","conditions":"Hepatitis C, Chronic","enrollment":1428},{"nctId":"NCT00686517","phase":"PHASE3","title":"Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-12","conditions":"Hepatitis C","enrollment":130},{"nctId":"NCT01447446","phase":"","title":"An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":4442},{"nctId":"NCT00277238","phase":"PHASE2","title":"CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-02","conditions":"Hepatitis, Chronic Active","enrollment":113},{"nctId":"NCT01463956","phase":"PHASE2","title":"Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2012-01-06","conditions":"HCV Infection, Liver Cirrhosis, Experimental","enrollment":58},{"nctId":"NCT01280656","phase":"","title":"A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Hepatitis C, Chronic","enrollment":660},{"nctId":"NCT01838772","phase":"PHASE4","title":"HCV Treatment in HIV Co-Infected Patients in Asia","status":"COMPLETED","sponsor":"amfAR, The Foundation for AIDS Research","startDate":"2013-12","conditions":"Hepatitis C, HIV","enrollment":188},{"nctId":"NCT01066819","phase":"","title":"PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":1656},{"nctId":"NCT01066793","phase":"","title":"PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Hepatitis C, Chronic","enrollment":2343},{"nctId":"NCT02168361","phase":"PHASE4","title":"The SIM-SOF Trial for Hepatitis C","status":"COMPLETED","sponsor":"Center For Hepatitis C, Atlanta, GA","startDate":"2013-12","conditions":"Chronic Hepatitis C","enrollment":93},{"nctId":"NCT00723645","phase":"","title":"Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-04","conditions":"Hepatitis C, Chronic","enrollment":279},{"nctId":"NCT00724464","phase":"","title":"Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":332},{"nctId":"NCT02204475","phase":"PHASE3","title":"Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-11","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT01016912","phase":"PHASE2","title":"Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatitis C Infection","enrollment":51},{"nctId":"NCT00726557","phase":"","title":"Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-10","conditions":"Hepatitis C, Chronic, Substance Abuse, Intravenous","enrollment":246},{"nctId":"NCT00725751","phase":"","title":"Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09","conditions":"Hepatitis C, Chronic","enrollment":353},{"nctId":"NCT00724373","phase":"","title":"Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11","conditions":"Hepatitis C, Chronic","enrollment":442},{"nctId":"NCT00724451","phase":"","title":"Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07","conditions":"Hepatitis C, Hepatitis C, Chronic","enrollment":1128},{"nctId":"NCT00724893","phase":"","title":"Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":2430},{"nctId":"NCT01579474","phase":"PHASE3","title":"Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-04","conditions":"Hepatitis C","enrollment":131},{"nctId":"NCT00705224","phase":"","title":"Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05","conditions":"Hepatitis C, Chronic, Hepatitis C Virus","enrollment":250},{"nctId":"NCT00856024","phase":"","title":"ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07","conditions":"Hepatitis C, Chronic","enrollment":902},{"nctId":"NCT01465516","phase":"","title":"Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir","status":"TERMINATED","sponsor":"Arrowhead Regional Medical Center","startDate":"2011-11","conditions":"Hepatitis C Infection","enrollment":105},{"nctId":"NCT00993122","phase":"PHASE4","title":"Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2009-10","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT01871662","phase":"PHASE2, PHASE3","title":"Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C","status":"WITHDRAWN","sponsor":"Rottapharm","startDate":"2013-08","conditions":"Hepatitis C, Chronic","enrollment":""},{"nctId":"NCT01405027","phase":"PHASE4","title":"Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy","status":"COMPLETED","sponsor":"Chronic Liver Disease Foundation","startDate":"2011-12","conditions":"Chronic Hepatitis C, Genotype 1","enrollment":197},{"nctId":"NCT00323804","phase":"PHASE2, PHASE3","title":"Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2006-05","conditions":"Hepatitis C, Chronic, Liver Fibrosis","enrollment":372},{"nctId":"NCT00528528","phase":"PHASE2","title":"An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2007-10","conditions":"Chronic Hepatitis C","enrollment":166},{"nctId":"NCT01045278","phase":"PHASE4","title":"Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy","status":"COMPLETED","sponsor":"Region Skane","startDate":"2008-04","conditions":"Hepatitis C","enrollment":277},{"nctId":"NCT01625793","phase":"NA","title":"Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes","status":"WITHDRAWN","sponsor":"University of Arizona","startDate":"2012-06","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT01025765","phase":"PHASE4","title":"The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2009-11","conditions":"Chronic Hepatitis C","enrollment":80},{"nctId":"NCT00279565","phase":"PHASE4","title":"Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)","status":"TERMINATED","sponsor":"Indivior Inc.","startDate":"2005-08","conditions":"Hepatitis C, Chronic","enrollment":128},{"nctId":"NCT01683786","phase":"PHASE4","title":"36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2011-08","conditions":"Hepatitis C Infection","enrollment":60},{"nctId":"NCT00230958","phase":"PHASE3","title":"Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2003-12","conditions":"Chronic Hepatitis C","enrollment":900},{"nctId":"NCT00593151","phase":"PHASE1, PHASE2","title":"Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Biolex Therapeutics, Inc.","startDate":"2008-01","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT00863239","phase":"PHASE2","title":"Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV","status":"COMPLETED","sponsor":"Biolex Therapeutics, Inc.","startDate":"2009-03","conditions":"Hepatitis C, Chronic","enrollment":116},{"nctId":"NCT00142103","phase":"PHASE1","title":"CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-09","conditions":"Hepatitis, Chronic Active","enrollment":91},{"nctId":"NCT00310336","phase":"PHASE2, PHASE3","title":"Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2006-08","conditions":"Hepatitis C","enrollment":30},{"nctId":"NCT00956982","phase":"NA","title":"PEG-IFN Plus Ribavirin Combination Therapy for Older Patients","status":"UNKNOWN","sponsor":"Kyushu University","startDate":"2004-12","conditions":"Hepatitis C Virus","enrollment":1251},{"nctId":"NCT00514111","phase":"","title":"Factors Associated to Success of Hepatitis C Therapy","status":"COMPLETED","sponsor":"UPECLIN HC FM Botucatu Unesp","startDate":"2007-08","conditions":"Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted","enrollment":100},{"nctId":"NCT00842205","phase":"NA","title":"Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection","status":"UNKNOWN","sponsor":"Charles University, Czech Republic","startDate":"2007-01","conditions":"Chronic HCV Infection, Nonalcoholic Steatohepatitis","enrollment":150},{"nctId":"NCT00543244","phase":"","title":"Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2006-01","conditions":"Chronic Hepatitis C","enrollment":300},{"nctId":"NCT00277758","phase":"PHASE1","title":"Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2004-03","conditions":"Hepatitis C","enrollment":18},{"nctId":"NCT00277862","phase":"PHASE4","title":"Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2002-04","conditions":"Hepatitis C","enrollment":280},{"nctId":"NCT00217139","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection","status":"COMPLETED","sponsor":"BioWest Therapeutics Inc","startDate":"2005-09","conditions":"Hepatitis C, Chronic","enrollment":60},{"nctId":"NCT00117533","phase":"PHASE4","title":"Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2005-09","conditions":"Chronic Hepatitis B, Chronic Hepatitis D","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"pegylated IFN alfa-2b plus ribavirin","genericName":"pegylated IFN alfa-2b plus ribavirin","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated interferon alfa-2b activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication. Used for Chronic hepatitis C virus infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}